ClinicalTrials.gg
RecruitingNCT07476170Updated Apr 2, 2026

Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

An observational study in HR+/HER2- Advanced or Metastatic Breast Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
14,000
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 200 studies in Breast Neoplasms by Novartis — 17 open to participants now, 31 under way, 4 of them phase 3. Breast Neoplasms · Novartis.

Planned enrollment
2nd of 39
14,000 · median 595
Started
2026
with 10 others
Observational
39 of 200
8 open now
Primary completion
2027-04
later than 7 of 30 live
Registered
190th of 200
by date

Among the 200 studies in Breast Neoplasms by Novartis, this one is the 2nd largest by planned enrollment of the 39 observational ones that give a count, is one of 11 that started in 2026, is one of 39 observational ones, reaches primary completion later than 7 of the 30 other live ones, and was the 190th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 200 studies in Breast Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Breast Neoplasms by Novartis, or all of them as a file.
02

Study summary

This study aims to fill the current gap in data regarding HR+/HER2- ABC 1L treatment patterns and outcomes in the real-world setting in China, especially in the context of the widespread application of CDK4/6is and the lack of sufficient evidence for ribociclib as a most recently marketed drug in the real-world setting.

Read the detailed description

This study is a longitudinal, non-interventional, retrospective, and observational study based on secondary real-world data in the National Anti-Tumor Drug Surveillance System (NATDSS) database. The study will not involve any active intervention, randomization, or control group.

All analyses will be conducted using Electronic Health Record (EHR) routinely collected in clinical practice and additional secondary data sources

03

Conditions studied

  • HR+/HER2- Advanced or Metastatic Breast Cancer

Browse trials for

Keywords

  • HR+/HER2- advanced or metastatic breast cancer
  • China,
  • NIS
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

HR+/HER2- ABC adult patients (aged 18 years or older) with 1L treatment being initiated between Jan. 1, 2024 and Jan. 1, 2027, and have at least 3 months of follow-up records after the initiation of 1L treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with HR+/- ABC:

    HR+ is defined as ER+ or PR+, and HER2+ is defined as immunohistochemistry 3+, or 2+ with positive in situ hybridization (amplification). Advanced or breast cancer is defined as having a documented inoperable clinical or pathological stage IIIB, IIIC, or IV, or the records indicating distant metastasis.

  2. Initiation of 1L anti-cancer treatment between Jan. 1, 2024 and Jan. 1, 2027; Defined as having records of systemic anti-cancer treatment in disease course records or order records within 90 days after the initial diagnosis of ABC, and receiving the first dose between Jan. 1, 2024 and Jan. 1, 2027, as recorded in the NATDSS database.
  3. Aged 18 years or older at the time of receiving the 1L treatment; Definition: The initiation date (index date) of 1L treatment is defined as the initiation date of systemic anti-cancer treatment for HR+/HER2- ABC first recorded in the database. Age will be preferentially calculated based on the date of birth (or year of birth) and the initiation date of 1L treatment in the database. If the birth information is not included in the database but shown in an "Age" field in the medical visit/hospitalization record associated with 1L treatment, this age field will be used as the basis for age.
  4. At least 3 months of follow-up records after the initiation of 1L treatment. Defined as having at least one outpatient or inpatient medical visit record in the NATDSS at least 3 months after the index date.

Exclusion criteria

Exclusion Criteria:

(1) Patients with any other concomitant invasive Defined as patients meeting any of the following conditions based on their diagnosis records in the cancer registry/medical database used for the study: 1. Within 5 years before the diagnosis of HR+/- ABC, there is a diagnosis record of invasive malignancy other than breast cancer in the database (based on the International Classification of Diseases [ICD] diagnosis code or cancer registry code), and the diagnosis is not carcinoma in situ or benign/borderline tumor; 2. On the day of, or within 3 months after, the diagnosis of HR+/HER2- ABC, there is a new diagnosis record of invasive malignancy at another site (also based on the ICD diagnosis code or cancer registry code) indicating a concomitant active malignancy.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
14,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Distribution of first-line treatment regimens

    Proportion of patients receiving each first line treatment category and specific regimen

    Time frame: Up to 39 months

  2. Proportion of patients with treatment changes

    Proportion of patients who discontinue or switch first line treatment

    Time frame: Up to 39 months

  3. Time to treatment initiation, time to discontinuation, and time to next line therapy

    Time to treatment initiation (TTI), time to discontinuation (TTD), and time to next-line therapy (TTNT)

    Time frame: Up to 39 months

  4. Proportion of patients by initial CDK4 6 inhibitor dose

    Proportion of patients treated with a CDK4 6 inhibitor, stratified by initial dose level

    Time frame: Up to 39 months

  5. Proportion of patients with dose modifications of CDK4/6 inhibitor therapy

    Proportion of patients treated with CDK4/6 inhibitor who experience any dose modification (including dose reduction and interruption)

    Time frame: Up to 39 months

  6. Time to first dose modification of CDK4/6 inhibitor therapy

    Time from initiation of CDK4/6 inhibitor therapy to the first dose modification, including dose reduction or interruption

    Time frame: Up to 39 months

Secondary outcomes

  1. rwPFS of 1L treatment patterns

    rwPFS is defined as the duration from the initiation date of 1L treatment to documented disease progression or death from any cause. If a patient has not experienced disease progression or death, the last confirmed survival time will be used as the censoring time to calculate the rwPFS censoring duration

    Time frame: Up to 39 months

  2. rwPFS of HR+/HER2- ABC patients

    rwPFS of HR+/HER2- ABC patients adhering or not adhering to the highest level of first-line treatment recommendation in the guidelines in the real-world setting based on the NATDSS database

    Time frame: Up to 39 months

  3. rwPFS of HR+/HER2- ABC patients receiving ribociclib-based 1L treatment regimens

    rwPFS of HR+/HER2- ABC patients receiving ribociclib-based 1L treatment regimens in the real-world setting based on the NATDSS database

    Time frame: Up to 39 months

  4. Number of subjects with AESIs

    AESIs under different treatment patterns, including: * Hematology: neutropenia, leukopenia, anemia, and thrombocytopenia; * Gastrointestinal tract: diarrhea, nausea, vomiting, stomatitis/mucositis; * QTc prolongation; * Hepatotoxicity: alanine transaminase (ALT)/aspartate transaminase (AST) increased, and total bilirubin increased.

    Time frame: Up to 39 months

  5. Baseline demographics

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative SIte
    Bingjie, Beijing Municipality 100021, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 17, 2026
StartActual
Mar 20, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476170
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Mar 20, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Apr 2, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion